Monday, January 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

CDC Contract to Texas A&M for Aflatoxin Research

by Global Biodefense Staff
July 16, 2014
Aflatoxin Research - Colony of Fungus

The Centers for Disease Control and Prevention intends to award a sole source, firm fixed price contract to Texas A&M. University researchers will process and analyze urine samples to measure aflatoxin ML and urine creatinine and provide assistance is disseminating study findings in Kenya.

Texas A&M has previously assessed the safety, palatability and efficacy of ACS100 clay limit of the absorption of fungal toxins from contaminated food in Africa and has supervised five human intervention trials of ACS100 clay in North America and Africa; and has performed mitigation of dietary and environmental risk factors for disease using absorbent clays in vulnerable populations of North America and Africa.

Texas A&M is the only provider of clay produced that has been extensively tested in Africa to reduce aflatoxin exposure without effecting micronutrient levels, according to the announcement.

Source: FBO.gov

Tags: Aflatoxin

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC